ライフサイエンスコーパス: enzyme-linked immunospot

1 after the treatment course, as determined by enzyme-linked immunospot.

2 by IFN-gamma-specific immunofluorescence and enzyme-linked immunospot.

3 vigorous cytotoxic T lymphocyte response by enzyme-linked immunospot.

4 ononuclear cells (PBMCs), were studied using enzyme-linked immunospot.

5 from 12/12 donors released IFN-gamma (50-300 enzyme-linked immunospots/200,000 T cells) and prolifera

6 Furthermore, enzyme-linked immunospot analyses demonstrated prominent

7 D4 T-cell epitopes within OMPs, we performed enzyme-linked immunospot analyses for gamma interferon (

8 Immunohistochemical, flow cytometric, and enzyme-linked immunospot analyses of the spleen, kidney,

9 Using enzyme-linked immunospot analysis (ELISPOT) assays, we f

10 of 32 HDV-infected patients were analyzed by enzyme-linked immunospot analysis and intracellular cyto

11 responses against A20 cells, as assessed via enzyme-linked immunospot analysis in vitro and immune pr

12 Enzyme-linked immunospot analysis reveals that these CTL

13 of IFN-gamma-secreting cytotoxic T cells by enzyme-linked immunospot analysis that may have also fac

14 cells were not detected by immunoglobulin M enzyme-linked immunospot analysis until day 7.

15 ell epitopes were mapped by gamma interferon enzyme-linked immunospot analysis using five overlapping

16 ed subjects not on antiretroviral therapy by enzyme-linked immunospot analysis with 53 peptide pools

17 cancer patients and 18 healthy donors using enzyme-linked immunospot analysis.

18 onor, as determined by tetramer staining and enzyme-linked immunospot analysis.

19 ic CD8(+) T cells were detected by IFN-gamma enzyme-linked immunospot and (51)Cr release assay in loc

20 l responses, as detected by interferon-gamma enzyme-linked immunospot and allo-antibody production, r

21 in BALB/c mice revealed that the DNA induced enzyme-linked immunospot and antigen-specific proliferat

22 A27, B5, L1, and A33, using gamma interferon enzyme-linked immunospot and cytokine flow cytometry ass

23 nd assessed HBV-specific T-cell responses by enzyme-linked immunospot and cytometric bead array.

24 r +/- tumor lysates were tested in gamma-IFN enzyme-linked immunospot and cytotoxicity assays.

25 P. falciparum by performing standardized MBC enzyme-linked immunospot and enzyme-linked immunosorbent

26 However, gamma interferon (IFN-gamma) enzyme-linked immunospot and IFN-gamma/tumor necrosis fa

27 Further, the IFN-gamma enzyme-linked ImmunoSPOT and in vitro 51Cr release assay

28 ses measured principally by gamma interferon enzyme-linked immunospot and neutralization assays were

29 ll responses were characterized by IFN-gamma enzyme-linked immunospot and whole blood intracellular c

30 Preliminary studies using enzyme-linked immunospot and Winn assays suggested that

31 esponder cell frequency and interferon-gamma enzyme-linked immunospot, and antibodies were measured b

32 (as measured by interferon gamma production, enzyme-linked immunospot, and CD137 upregulation assays)

33 IAP, as revealed by proliferation, tetramer, enzyme-linked immunospot, and cytotoxicity analysis.

34 Results from functional analyses by DTH, enzyme-linked immunospot, and immunohistofluorescence as

35 ukin 2, 4, 5, and 6 were counted by means of enzyme-linked immunospot, and SFC counts were compared b

36 response to HCV antigens were enumerated by Enzyme Linked Immunospot Assay.

37 ysis), and more IFN-gamma-secreting cells by enzyme-linked immunospot assay (1460 vs 280 IFN-gamma sp

38 ls developed neutralizing antibodies and low enzyme-linked immunospot assay (E-SPOT) titers against S

39 Enzyme-linked immunospot assay (ELISPOT) analysis of pso

40 ssed by ex vivo gamma interferon (IFN-gamma) enzyme-linked immunospot assay (ELISPOT) and antibody as

41 LSA-1 and TRAP peptides were assessed by the enzyme-linked immunospot assay (ELISPOT) and enzyme-link

42 to detect autoreactive responses when using enzyme-linked immunospot assay (ELISPOT) and enzyme-link

43 ere detected by interferon-gamma (IFN-gamma) enzyme-linked immunospot assay (ELISPOT) assays using th

44 Gamma interferon (IFN-gamma) measured by enzyme-linked immunospot assay (ELISPOT) at multiple tim

45 We used flow cytometry and enzyme-linked immunospot assay (ELISPOT) to examine B-ce

46 We used the ex vivo IFN-gamma enzyme-linked immunospot assay (ELISpot) to track T cell

47 antigen-specific IFN-gamma production in an enzyme-linked immunospot assay (ELISPOT).

48 after allogeneic BMT using gamma-interferon enzyme-linked immunospot assay (ELISPOT).

49 tion, and measured antibody-secreting cells (enzyme-linked immunospot assay [ELISPOT]) as an early ma

50 phisms with cellular (interferon [IFN] gamma enzyme-linked immunospot assay [ELISPOT]) immune respons

51 ted in these animals by the gamma interferon enzyme-linked immunospot assay against pools of short ov

52 specific CD8+ CTL responses were detected by enzyme-linked immunospot assay against several NY-BR-1 p

53 lobulin M antibody-secreting cells (ASCs) by enzyme-linked immunospot assay allowed for differentiati

54 Cultured enzyme-linked immunospot assay analysis demonstrated tha

55 lar sensitization was detected by performing enzyme-linked immunospot assay analysis for cytokines in

56 ce data of specific genes were combined with enzyme-linked immunospot assay analysis of critical epit

57 Enzyme-linked immunospot assay analysis of peripheral T-

58 rus-specific T-cell responses by means of an enzyme-linked immunospot assay and antibody responses by

59 A antibody-secreting B cells was analyzed by enzyme-linked immunospot assay and by analysis of Epstei

60 Enzyme-linked immunospot assay and ELISA analysis were r

61 (+) T cells, as detected by interferon gamma enzyme-linked immunospot assay and flow cytometry, were

62 he vaccine and drifted A(H3N2) viruses by an enzyme-linked immunospot assay and flow cytometry.

63 By gamma interferon enzyme-linked immunospot assay and intracellular cytokin

64 ion assay) and T cell responses (measured by enzyme-linked immunospot assay and intracellular cytokin

65 ain SCC-derived antigens using the IFN-gamma enzyme-linked immunospot assay and intratumor (IT) and c

66 at multiple time points by interferon-gamma enzyme-linked immunospot assay and was correlated to the

67 tified memory responses measured by cultured enzyme-linked immunospot assay as well as in vitro inter

68 e measured in 9 patients by interferon-gamma enzyme-linked immunospot assay at 3 time points within 1

69 in the blood by gamma interferon (IFN-gamma) enzyme-linked immunospot assay at select time points; ho

70 re likely to have a positive response to ASC enzyme-linked immunospot assay at the late time point th

71 T-cell responses were analyzed using T-cell enzyme-linked immunospot assay before convalescent plasm

72 a virus were detected by an interferon gamma enzyme-linked immunospot assay but had no clear relation

73 analyzed in the gamma interferon (IFN-gamma)-enzyme-linked immunospot assay by using synthetic overla

74 An Ag-specific B cell enzyme-linked immunospot assay confirmed these results a

75 FITC/DNFB skin painting and subsequent enzyme-linked immunospot assay demonstrated that flow-so

76 1 subject, antigen-specific interferon-gamma enzyme-linked immunospot assay detected an immunogenic d

77 e further confirmed by the results of CD4(+) enzyme-linked immunospot assay for interferon (IFN)-gamm

78 ng was performed using a CEA peptide and the enzyme-linked immunospot assay for interferon gamma prod

79 , and GAD65 peptides) were measured by IL-17 enzyme-linked immunospot assay in patients with new-onse

80 berculosis strain H37Rv as a stimulant in an enzyme-linked immunospot assay in sensitized individuals

81 ), and in healthy control subjects (n=10) by enzyme-linked immunospot assay in the presence and absen

82 validation cohort were measured by IFN-gamma enzyme-linked immunospot assay or intracellular cytokine

83 ed a 10- to 40-fold increase in HIV-specific enzyme-linked immunospot assay responses compared to tho

84 mmunosorbent assay titers, and EnvA-specific enzyme-linked immunospot assay responses, and these resp

85 Enzyme-linked immunospot assay results indicated that th

86 y higher numbers of spot-forming cells in an enzyme-linked immunospot assay than did T cells primed w

87 t gamma interferon production, determined by enzyme-linked immunospot assay to at least one of the th

88 1 transgenic NOD mice in an interferon-gamma enzyme-linked immunospot assay to identify autoantigenic

89 D8 T cell responses were quantified using an enzyme-linked immunospot assay to measure interferon-gam

90 MI responses by interferon gamma (IFN-gamma) enzyme-linked immunospot assay using 3 recombinant HCV p

91 eens of immunized mice by a gamma interferon enzyme-linked immunospot assay using peptides derived fr

92 gamma interferon-producing cells detected by enzyme-linked immunospot assay was increased (P < 0.01 f

93 Using enzyme-linked immunospot assay we found higher frequenci

94 Mycoplasma pneumoniae ASCs measured by enzyme-linked immunospot assay were assessed alongside M

95 asured by gamma interferon and interleukin 2 enzyme-linked immunospot assay were significantly higher

96 MPO-specific T cells were quantified by enzyme-linked immunospot assay with additional Treg cell

97 mined by intracellular cytokine staining and enzyme-linked immunospot assay) and produced anti-PR8 an

98 ss I Gag-tetramer staining, gamma interferon-enzyme-linked immunospot assay, and cytotoxic T-cell ass

99 ays, antigen-specific interferon (IFN)-gamma enzyme-linked immunospot assay, and enzyme-linked immuno

100 ern blot, delayed type hypersensitivity, and enzyme-linked immunospot assay, and reduced the number o

101 d multiparameter flow cytometric sorting and enzyme-linked immunospot assay, demonstrate that anti-Ga

102 ific T cells, enumerated by gamma interferon enzyme-linked immunospot assay, did not appear until 2 w

103 y-secreting cells (ASC) in blood measured by enzyme-linked immunospot assay, the antibody in lymphocy

104 s-specific CD4 responses by gamma interferon enzyme-linked immunospot assay, using 410 overlapping pe

105 An interferon-gamma enzyme-linked immunospot assay, using peptide pools span

106 assay and/or ex vivo interferon (IFN)-gamma enzyme-linked immunospot assay, was documented in 45.5%

107 Using an enzyme-linked immunospot assay, we evaluated immunoglobu

108 Using flow cytometric analysis and enzyme-linked immunospot assay, we examined peripheral n

109 a interferon-secreting cells, as detected by enzyme-linked immunospot assay, were obtained in respons

110 cing CD4(+) T cell responses, as assessed by enzyme-linked immunospot assay, were significantly more

111 )-4-secreting cells were determined using an enzyme-linked immunospot assay, which demonstrated that

112 Viral loads, CD4(+) T-cell counts, and enzyme-linked immunospot assay-determined anti-HIV-1 CD8

113 e assessed using an ex-vivo interferon-gamma enzyme-linked immunospot assay.

114 s were detected by gamma interferon-specific enzyme-linked immunospot assay.

115 B cell Ig isotype switching was measured by enzyme-linked immunospot assay.

116 tibody-secreting cells were enumerated using enzyme-linked immunospot assay.

117 assays, intracelluar cytokine staining, and enzyme-linked immunospot assay.

118 l responses were assayed by interferon-gamma enzyme-linked immunospot assay.

119 ymphocyte proliferation and interferon gamma enzyme-linked immunospot assay.

120 racheobronchial lymph nodes as determined by enzyme-linked immunospot assay.

121 and in 22 (73%) of 30 vaccine recipients by enzyme-linked immunospot assay.

122 emory responses were evaluated by IFN- gamma enzyme-linked immunospot assay.

123 ulated memory B cells were detected using an enzyme-linked immunospot assay.

124 , and IL-6 cytokines as measured by cytokine enzyme-linked immunospot assay.

125 producing gamma interferon when analyzed by enzyme-linked immunospot assay.

126 producing B cells could still be detected by enzyme-linked immunospot assay.

127 5, 7, and 14 postgrafting, as measured by an enzyme-linked immunospot assay.

128 +) T lymphocytes were induced as analyzed by enzyme-linked immunospot assay.

129 h nodes, lungs, and Peyer's patches using an enzyme-linked immunospot assay.

130 -positive, HLA A2-positive individuals in an enzyme-linked immunospot assay.

131 pond to HIV-1 peptides in a gamma interferon enzyme-linked immunospot assay.

132 T-cell responses by using a gamma interferon enzyme-linked immunospot assay.

133 ed in the various tissues of GalT-/- mice by enzyme-linked immunospot assay.

134 us peptides via interferon-gamma (IFN-gamma) enzyme-linked immunospot assay.

135 mic lymphoid tissues were evaluated using an enzyme-linked immunospot assay.

136 red in peripheral blood mononuclear cells by enzyme-linked immunospot assay.

137 body assay, and an interferon gamma-specific enzyme-linked immunospot assay.

138 ses were assessed using an ex-vivo IFN-gamma enzyme-linked immunospot assay.

139 body- forming cells were determined using an enzyme-linked immunospot assay.

140 cells measured before challenge by cultured enzyme-linked immunospot assay.

141 and dsDNA antibody-secreting cells (ASCs) by enzyme-linked immunospot assay.

142 ral suppression assay (VSA) and an IFN-gamma enzyme-linked immunospot assay.

143 red by enzyme-linked immunosorbent assay and enzyme-linked immunospot assay.

144 mmunity to SHIV89.6 peptides was measured by enzyme-linked immunospot assay; strong responses to Gag

145 ent assays (ELISA) titers, and EnvA-specific enzyme-linked immunospot assays (ELISPOT) responses.

146 mune responses were measured by tetramer and enzyme-linked immunospot assays against gp100 and MART-1

147 e compared by standardized interferon- gamma enzyme-linked immunospot assays among 250 unvaccinated i

148 Enzyme-linked immunospot assays confirmed this high freq

149 Spleen cells were phenotyped, and enzyme-linked immunospot assays for autoantibody-produci

150 cluding MHC class I tetramer binding assays, enzyme-linked immunospot assays for IFN-gamma production

151 cells that recognize EBV-latent antigens in enzyme-linked immunospot assays for interferon gamma sec

152 BL/6 beta-gal transgenic skin were tested in enzyme-linked immunospot assays for recall responses to

153 c CD8(+)-T-cell responses were determined by enzyme-linked immunospot assays in 150 HIV-infected indi

154 s shown by cytotoxicity and interferon gamma enzyme-linked immunospot assays in six of nine patients.

155 immune-sensitization using the B and T-cell enzyme-linked immunospot assays may identify CMV-sensiti

156 eins were used to screen 15 normal donors in enzyme-linked immunospot assays of gamma interferon rele

157 pping peptides and gamma interferon-specific enzyme-linked immunospot assays of peripheral blood mono

158 Results of enzyme-linked immunospot assays of the immunized mice re

159 were assessed using interferon (IFN)- gamma enzyme-linked immunospot assays on peripheral blood mono

160 Interferon-gamma (IFN-gamma) enzyme-linked immunospot assays on peripheral blood mono

161 s of Candida-specific T-cell responses using enzyme-linked immunospot assays revealed higher numbers

162 Proliferation and gamma interferon enzyme-linked immunospot assays using peripheral blood l

163 Interferon gamma (IFN-gamma) enzyme-linked immunospot assays were performed before an

164 Enzyme-linked immunospot assays were performed to confir

165 Enzyme-Linked ImmunoSpot assays yielded parallel results

166 production in mixed lymphocyte reaction and enzyme-linked immunospot assays, respectively.

167 nterferon (IFN)-gamma and interleukin (IL)-5 enzyme-linked immunospot assays, respectively.

168 By use of enzyme-linked immunospot assays, the percentages of memo

169 s, trans-vivo delayed-type hypersensitivity, enzyme-linked immunospot assays, the use of antigen rece

170 ic T cells were measured by interferon-gamma enzyme-linked immunospot assays, using recombinant vacci

171 wild-type sequence was also demonstrated by enzyme-linked immunospot assays.

172 A-matched peptides by using gamma interferon enzyme-linked immunospot assays.

173 pol regimen, as measured by gamma interferon enzyme-linked immunospot assays.

174 T-cell responses as measured using IFN-gamma enzyme-linked immunospot assays.

175 DNA cells by IFN-gamma-secretion measured in enzyme-linked immunospot assays.

176 ls in both cytotoxicity assays and IFN-gamma enzyme-linked immunospot assays.

177 the lamina propria of the small intestine by enzyme-linked immunospot assays.

178 d mononuclear cells using flow cytometry and enzyme-linked immunospot assays.

179 aining, and fine mapping in interferon-gamma enzyme-linked immunospot assays.

180 cell responses, measured by interferon gamma enzyme-linked immunospot assays.

181 ld in-tube test (ELISA), and T-SPOT.TB test (enzyme-linked immunospot) at 17 centers in 11 European c

182 Enzyme-linked immunospots, cytotoxicity assays as well a

183 phore linked immunosorbent assay (FLISA) and enzyme linked immunospotting (ELISPOT).

184 This result was supported by enzyme-linked immunospot (ELISPOT) analyses indicating c

185 erferon (IFN-gamma) and interleukin-5 (IL-5) enzyme-linked immunospot (ELISPOT) analyses were used to

186 Using high resolution enzyme-linked immunospot (ELISPOT) analysis, we have rev

187 )-producing CD8(+) T cells, as determined by enzyme-linked immunospot (ELISPOT) analysis.

188 isease, CMV-specific interferon (IFN)- gamma enzyme-linked immunospot (ELISPOT) and CD8(+) and CD4(+)

189 the same protein following RSV infection by enzyme-linked immunospot (ELISPOT) and intracellular cyt

190 tricted epitope using interferon (IFN)-gamma enzyme-linked immunospot (ELISPOT) and intracellular cyt

191 Acute Hepatitis C (ATAHC), using HCV peptide enzyme-linked immunospot (ELISPOT) and multiplex in vitr

192 ctly ex vivo by gamma interferon (IFN-gamma) enzyme-linked immunospot (ELISPOT) assay (P = 2 x 10(-10

193 cific IgM antibody-secreting cells (ASCs) by enzyme-linked immunospot (ELISpot) assay allowed for dif

194 tive allo-HCT recipients with a CMV-specific enzyme-linked immunospot (ELISPOT) assay and for CMV inf

195 epitopes measured by interferon (IFN)-gamma enzyme-linked immunospot (ELISPOT) assay and HLA/peptide

196 nd lytic antigens by interferon (IFN)- gamma enzyme-linked immunospot (ELISPOT) assay and interleukin

197 responses, as indicated by gamma interferon enzyme-linked immunospot (ELISPOT) assay and intracellul

198 zed mice as determined by using quantitative enzyme-linked immunospot (ELISpot) assay and intracellul

199 Interferon-gamma enzyme-linked immunospot (ELISPOT) assay and tetramer an

200 We have developed a gamma interferon enzyme-linked immunospot (ELISPOT) assay for evaluation

201 ere screened by gamma interferon (IFN-gamma) enzyme-linked immunospot (ELISPOT) assay for HLA class I

202 With an enzyme-linked immunospot (ELISPOT) assay for interferon

203 A highly sensitive enzyme-linked immunospot (ELISPOT) assay for single cell

204 ned using a sensitive interferon (IFN)-gamma enzyme-linked immunospot (ELISPOT) assay in 187 Caucasia

205 IgG-secreting cells were detected by enzyme-linked immunospot (ELISPOT) assay in cell suspens

206 Quantification of interferon (IFN)-gamma by enzyme-linked immunospot (ELISPOT) assay is currently us

207 compared the HIV-specific ex vivo IFN-gamma enzyme-linked immunospot (ELISPOT) assay responses of 19

208 Gamma interferon (IFN-gamma) enzyme-linked immunospot (ELISPOT) assay responses targe

209 nstrated VV-specific interferon (IFN)- gamma enzyme-linked immunospot (ELISPOT) assay responses; 21 (

210 to HSV-2 directly, ex vivo, we developed an enzyme-linked immunospot (ELISPOT) assay that utilized p

211 common cold coronaviruses.METHODSWe used the enzyme-linked immunospot (ELISPOT) assay to characterize

212 We developed and assessed a sensitive enzyme-linked immunospot (ELISPOT) assay to detect T cel

213 nized NZB/NZW mice were analyzed in vitro by enzyme-linked immunospot (ELISpot) assay to determine T

214 ecific responses in the vaccinia virus-based enzyme-linked immunospot (Elispot) assay using a panel o

215 The enzyme-linked Immunospot (ELISPOT) assay was used to det

216 y full-proteome gamma interferon (IFN-gamma) enzyme-linked immunospot (ELISPOT) assay were restricted

217 hort-term T-lymphocyte cell lines, IFN-gamma enzyme-linked immunospot (ELISPOT) assay with peripheral

218 responses were detected by use of a modified enzyme-linked immunospot (ELISpot) assay with recombinan

219 body-secreting cells (ASCs) were measured by enzyme-linked immunospot (ELISPOT) assay, and antibody r

220 Tetramer staining, enzyme-linked immunospot (ELISPOT) assay, and cytotoxici

221 Here the enzyme-linked immunospot (ELISPOT) assay, intracellular

222 as assessed by gamma interferon (IFN-gamma) enzyme-linked immunospot (ELISPOT) assay.

223 mulation and assessed IFN-gamma secretion by enzyme-linked immunospot (Elispot) assay.

224 ed Env-specific immunoglobulin G (IgG) in an enzyme-linked immunospot (ELISPOT) assay.

225 were determined by using an interferon-gamma enzyme-linked immunospot (ELISpot) assay.

226 recombinant vaccinia vectors was measured by enzyme-linked immunospot (ELISPOT) assay.

227 rs with the same peptide pools in a cultured enzyme-linked immunospot (ELISPOT) assay.

228 pressed HIV-1 proteins in a gamma interferon-enzyme-linked immunospot (Elispot) assay.

229 and in vitro by mixed leukocyte reaction and enzyme-linked immunospot (ELISPOT) assay.

230 creting T cells in the hosts was measured by enzyme-linked immunospot (ELISPOT) assay.

231 quantified for all subjects in an IFN-gamma enzyme-linked immunospot (ELISpot) assay.

232 r flow cytometry, flow antibody binding, and enzyme-linked immunospot (ELISpot) assay.

233 8-27) pentamer staining and CD8(+) IFN-gamma enzyme-linked immunospot (ELISPOT) assay.

234 using peripheral blood mononuclear cells in enzyme-linked immunospot (Elispot) assays and using CTL

235 In this study, sensitive enzyme-linked immunospot (elispot) assays have been util

236 detected by interferon (IFN) gamma and IL-2 enzyme-linked immunospot (ELISPOT) assays in 50% and 40%

237 pecific IFN-gamma responses were detected by enzyme-linked immunospot (ELISPOT) assays in all subject

238 However, validated enzyme-linked immunospot (ELISpot) assays of influenza-s

239 ivity to escape variant peptides in standard enzyme-linked immunospot (ELISPOT) assays predicts the r

240 tantial CD8(+) T cell responses by IFN-gamma enzyme-linked immunospot (ELISPOT) assays to all 11 of t

241 In this study, we performed quantitative enzyme-linked immunospot (ELISPOT) assays to measure loc

242 CMV immunoglobulin G (IgG) avidity and CMV enzyme-linked immunospot (ELISpot) assays were employed

243 In interferon-gamma (IFN-gamma) enzyme-linked immunospot (ELISPOT) assays, antiviral res

244 Using IFN-gamma and interleukin (IL)-2 enzyme-linked immunospot (ELISpot) assays, we analyzed t

245 Using tetramer and enzyme-linked immunospot (ELISPOT) assays, we have obser

246 es in enzyme immunoassay, proliferation, and enzyme-linked immunospot (ELISpot) assays.

247 um-release and confirmatory interferon-gamma enzyme-linked immunospot (ELISPOT) assays.

248 N-gamma) responses to the peptide epitope in enzyme-linked immunospot (ELISPOT) assays.

249 (MHC) tetramer staining and gamma interferon enzyme-linked immunospot (ELISPOT) assays.

250 unique to the seasonal or pandemic strain by enzyme-linked immunospot (ELISpot) assays.

251 interferon-gamma (IFN-gamma) release by CD4 enzyme-linked immunospot (ELISPOT) at one or more time p

252 lass II cellular immunity was analyzed using enzyme-linked immunospot (ELISPOT) by testing recipient

253 rferon gamma (IFN-gamma) production using an enzyme-linked immunospot (ELISPOT) CMV assay (T-SPOT.CMV

254 y (CMV-CMI) as determined by a peptide-based enzyme-linked immunospot (ELISPOT) CMV assay may identif

255 The enzyme-linked immunospot (Elispot) gamma interferon assa

256 ysaccharide cellular immunity, measured with enzyme-linked immunospot (ELISPOT) interferon gamma rele

257 tionated HIV-1 gag-specific interferon gamma enzyme-linked immunospot (ELISpot) response 4 weeks afte

258 Enzyme-linked immunospot (ELISpot) showed no interferon-

259 By contrast, enzyme-linked immunospot (ELISPOT), flow cytometry, time

260 ll responses were assessed in proliferation, enzyme-linked immunospot (ELISPOT), interferon (IFN)-gam

261 pping HCV peptides and 6 proteins by ex vivo enzyme-linked immunospot (ELISpot), intracellular cytoki

262 Analyses included IFN-gamma enzyme-linked immunospot (ELISPOT), reverse transcriptio

263 T-cell responses as determined by IFN-gamma enzyme-linked immunospot (ELISPOT), tetramer, and cytoto

264 peripheral blood lymphocyte gamma interferon enzyme-linked immunospot (ELISPOT), tetramer, and intrac

265 r tissues and analyzed by flow cytometry and enzyme-linked ImmunoSpot (ELISpot).

266 unoglobulin (Ig) A antibody-secreting cells (enzyme-linked immunospot [ELISPOT] assay), IgG serologic

267 alpha, or CD40L), and more ex vivo IFN-gamma enzyme-linked immunospots (ELISPOTs) than did the RTS,S/

268 of 500 to 1,000 gamma interferon (IFN-gamma) enzyme-linked immunospots (ELISPOTS)/10(6) peripheral bl

269 T-cell responses were studied by enzyme-linked immunospot for interferon-gamma.

270 change between pre-study and postvaccination enzyme-linked immunospot frequency of purified CD8 T-cel

271 parameters, cell-mediated immunogenicity by enzyme-linked immunospot, functional neutralizing antibo

272 s (VZV) T-cell responses by interferon-gamma enzyme-linked immunospot (IFN-gamma ELISPOT) and VZV ant

273 sorbent assay (gpELISA) and interferon-gamma enzyme-linked immunospot (IFN-gamma ELISPOT), blood samp

274 cell proliferative responses, and cytokines (enzyme-linked immunospot) in 48 subjects with unresolved

275 Enzyme-linked immunospot, intracellular cytokine stainin

276 ce was assessed by skin and heart grafts and enzyme-linked immunospot, intracellular cytokine, and mi

277 flow cytometry for cell surface markers and enzyme-linked immunospot methods to assess the subset di

278 llograft recipients was evaluated ex vivo by enzyme-linked immunospot, mixed lymphocytes reaction, cy

279 Using interferon-gamma enzyme-linked immunospot, Mtb39-specific CD8+ T lymphocy

280 ers and T-cell immunity to AAV, validated by enzyme-linked immunospot on the second day after gene in

281 = 0.0043), IFN-gamma production measured by enzyme-linked immunospot (P < 0.0001), and multiplex cyt

282 sed by enzyme-linked immunosorbent assay and enzyme-linked immunospot performed at baseline and from

283 Furthermore, positive enzyme-linked immunospot reactions to belagenpumatucel-L

284 gnitude of the SIV-specific gamma interferon enzyme-linked immunospot response.

285 A hierarchy was observed in enzyme-linked immunospot responses (with the strongest r

286 ys developed high-frequency gamma interferon enzyme-linked immunospot responses against BCG purified

287 animals developed vigorous gamma interferon enzyme-linked immunospot responses and moderate prolifer

288 We assessed KSHV-specific interferon- gamma enzyme-linked immunospot responses in a cohort of 154 in

289 pment of neutralizing antibody and IFN-gamma enzyme-linked immunospot responses to AAV1 capsid at day

290 gnitude and the breadth of interferon- gamma enzyme-linked immunospot responses were inversely correl

291 IFN- gamma enzyme-linked immunospot responses were significantly di

292 interferon (IFN)-gamma secretion, IFN-gamma enzyme-linked immunospot responses, and direct ex vivo i

293 strong ex vivo tetramer and interferon gamma enzyme-linked immunospot responses, and endogenous expre

294 d II were used to stimulate interferon-gamma enzyme-linked immunospot responses.

295 e ELISA (1.31 cases per 100 person-years) or enzyme-linked immunospot result (1.78 cases per 100 pers

296 ated cell sorter, mixed lymphocyte reaction, enzyme-linked immunospot, signaling studies, and a rat m

297 We previously introduced an enzyme-linked immunospot spot (ELISpot)-based assay to m

298 anti-Salmonella mucosal immune responses by enzyme-linked immunospot studies.

299 ear cells were tested using interferon-gamma enzyme-linked immunospot T assays measuring the response

300 Postchallenge enzyme-linked immunospot values for Gag and Env as well